Recent Posts
- Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices
- Elutia Celebrates First Year; Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment
- Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
- Elutia to Participate in Upcoming Investor Conferences
- Elutia Announces Second Quarter 2024 Results Launch; Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position Solidified